ES2054753T3 - Conjugados de citoquinas con inmunoglobulinas. - Google Patents

Conjugados de citoquinas con inmunoglobulinas.

Info

Publication number
ES2054753T3
ES2054753T3 ES88114130T ES88114130T ES2054753T3 ES 2054753 T3 ES2054753 T3 ES 2054753T3 ES 88114130 T ES88114130 T ES 88114130T ES 88114130 T ES88114130 T ES 88114130T ES 2054753 T3 ES2054753 T3 ES 2054753T3
Authority
ES
Spain
Prior art keywords
conjugates
immunoglobulins
cytokines
cytokine
tumours
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES88114130T
Other languages
English (en)
Inventor
Wussow Peter Dr Von
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Ciba Geigy AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ciba Geigy AG filed Critical Ciba Geigy AG
Application granted granted Critical
Publication of ES2054753T3 publication Critical patent/ES2054753T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07G—COMPOUNDS OF UNKNOWN CONSTITUTION
    • C07G99/00—Subject matter not provided for in other groups of this subclass
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/212—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A61K47/6813—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin the drug being a peptidic cytokine, e.g. an interleukin or interferon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies

Abstract

LA PRESENTE PATENTE AFECTA A NUEVOS CONJUGADOS COMPUESTOS POR UNA CITOCINA, P.E. INTERFERON ALFA, Y POR INMUNOGLOBULINA HUMANA, SI SE DESEA UNIDOS SOBRE UN FORMADOR DE PUENTES ORGANICO; PROCESO PARA LA PRODUCCION DE ESTOS CONJUGADOS, PREPARACIONES FARMACEUTICAS Y EL USO DE ESTOS CONJUGADOS PARA EL TRATAMIENTO DE INFECCIONES VIRALES Y DE TUMORES. FRENTE A LA CITOCINA LIBRE MUESTRAN ESTOS CONJUGADOS UN MAYOR TIEMPO DE PERMANENCIA EN PLASMA Y TEJIDOS, CON LO QUE MEJORAN EL EFECTO TERAPEUTICO.
ES88114130T 1987-09-02 1988-08-30 Conjugados de citoquinas con inmunoglobulinas. Expired - Lifetime ES2054753T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CH335787 1987-09-02

Publications (1)

Publication Number Publication Date
ES2054753T3 true ES2054753T3 (es) 1994-08-16

Family

ID=4254228

Family Applications (1)

Application Number Title Priority Date Filing Date
ES88114130T Expired - Lifetime ES2054753T3 (es) 1987-09-02 1988-08-30 Conjugados de citoquinas con inmunoglobulinas.

Country Status (15)

Country Link
EP (1) EP0305967B1 (es)
JP (1) JPS6490200A (es)
KR (1) KR890005137A (es)
AT (1) ATE88900T1 (es)
AU (1) AU627694B2 (es)
DE (1) DE3880766D1 (es)
DK (1) DK486588A (es)
ES (1) ES2054753T3 (es)
FI (1) FI884013A (es)
IL (1) IL87621A0 (es)
NO (1) NO883896L (es)
NZ (1) NZ226005A (es)
PH (1) PH26813A (es)
PT (1) PT88385B (es)
ZA (1) ZA886471B (es)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3818055A1 (de) * 1988-05-27 1989-11-30 Biotest Pharma Gmbh Kombination aus humanen immunglobulinen und interleukin-2 zur bekaempfung von infektionskrankheiten
GB8820378D0 (en) * 1988-08-26 1988-09-28 Offord R E Chemical compounds
GB8820377D0 (en) * 1988-08-26 1988-09-28 Offord R E Chemical compounds
KR900005995A (ko) * 1988-10-31 1990-05-07 우메모또 요시마사 변형 인터류킨-2 및 그의 제조방법
DE3839332A1 (de) * 1988-11-22 1990-05-23 Bayer Ag Verfahren zur herstellung von substituierten 2-chlorpyridinen
IE63847B1 (en) * 1989-05-05 1995-06-14 Res Dev Foundation A novel antibody delivery system for biological response modifiers
US5527527A (en) * 1989-09-07 1996-06-18 Alkermes, Inc. Transferrin receptor specific antibody-neuropharmaceutical agent conjugates
US5977307A (en) * 1989-09-07 1999-11-02 Alkermes, Inc. Transferrin receptor specific ligand-neuropharmaceutical agent fusion proteins
US5182107A (en) * 1989-09-07 1993-01-26 Alkermes, Inc. Transferrin receptor specific antibody-neuropharmaceutical or diagnostic agent conjugates
US5154924A (en) * 1989-09-07 1992-10-13 Alkermes, Inc. Transferrin receptor specific antibody-neuropharmaceutical agent conjugates
US5314995A (en) * 1990-01-22 1994-05-24 Oncogen Therapeutic interleukin-2-antibody based fusion proteins
US5349053A (en) * 1990-06-01 1994-09-20 Protein Design Labs, Inc. Chimeric ligand/immunoglobulin molecules and their uses
US5478804A (en) * 1990-09-19 1995-12-26 The Salk Institute For Biological Studies Treatment of tumorigenic pathophysiological conditions with FGF-cytoxic conjugates
EP0565620B1 (en) * 1991-01-03 1995-09-20 The Salk Institute For Biological Studies Mitotoxin for treatment of vascular injury
ATE141515T1 (de) * 1991-02-04 1996-09-15 Univ Saskatchewan Arzneistoffabgabe aus vp6-kapseln
PT100090A (pt) * 1991-02-04 1993-07-30 Univ Saskatchewan Metodo de preparacao de uma composicao capz de libertar um agente biologicamente activo para um alvo, e de encapsulacao do referido agente em esferas da proteina vp6
JP3105629B2 (ja) * 1991-04-23 2000-11-06 サングスタット メディカル コーポレイション 特異的結合ペアのメンバーの細胞活性調節接合体
EP0533006A1 (en) * 1991-09-18 1993-03-24 F.Hoffmann-La Roche & Co. Aktiengesellschaft Chimaeric interleukin 5-receptor/immunoglobulin polypeptides
US7754211B2 (en) 1992-04-10 2010-07-13 Research Development Foundation Immunotoxins directed against c-erbB-2(HER-2/neu) related surface antigens
US6030613A (en) * 1995-01-17 2000-02-29 The Brigham And Women's Hospital, Inc. Receptor specific transepithelial transport of therapeutics
US6086875A (en) * 1995-01-17 2000-07-11 The Brigham And Women's Hospital, Inc. Receptor specific transepithelial transport of immunogens
US6485726B1 (en) 1995-01-17 2002-11-26 The Brigham And Women's Hospital, Inc. Receptor specific transepithelial transport of therapeutics
US6015555A (en) * 1995-05-19 2000-01-18 Alkermes, Inc. Transferrin receptor specific antibody-neuropharmaceutical or diagnostic agent conjugates
AU2610097A (en) * 1996-04-10 1997-10-29 Sangstat Medical Corporation Cytomodulating conjugates of members of specific binding pairs
IT1289608B1 (it) * 1997-02-05 1998-10-15 Angelini Ricerche Spa Composizione per uso terapeutico o diagnostico somministrabile per via intranasale,sublinguale o vaginale
CA2312188C (en) 1997-12-08 2010-06-29 Lexigen Pharmaceuticals Corp. Heterodimeric fusion proteins useful for targeted immune therapy and general immune stimulation
SK782002A3 (en) 1999-07-21 2003-08-05 Lexigen Pharm Corp FC fusion proteins for enhancing the immunogenicity of protein and peptide antigens
US6617135B1 (en) 1999-08-09 2003-09-09 Emd Lexigen Research Center Corp. Multiple cytokine protein complexes
DK1252192T3 (da) 2000-02-11 2006-11-20 Merck Patent Gmbh Forbedring af antistofbaserede fusionsproteiners serumhalveringstid
JP5059271B2 (ja) 2000-03-31 2012-10-24 パーデュー・リサーチ・ファウンデイション リガンド免疫原複合体を用いる処置方法
ZA200305980B (en) 2001-02-12 2007-01-31 Res Dev Foundation Modified proteins, designer toxins, and methods of making thereof
MXPA03008031A (es) 2001-03-07 2003-12-04 Merck Patent Gmbh Tecnologia de expresion para proteinas que contienen porcion de anticuerpo isotipo hibrida.
WO2002079415A2 (en) 2001-03-30 2002-10-10 Lexigen Pharmaceuticals Corp. Reducing the immunogenicity of fusion proteins
DK1383785T3 (da) 2001-05-03 2011-05-23 Merck Patent Gmbh Rekombinant tumorspecifikt antistof og anvendelse deraf
AU2002327310B2 (en) 2001-07-17 2006-09-28 Research Development Foundation Therapeutic agents comprising pro-apoptotic proteins
AU2002357784B2 (en) 2001-12-04 2008-07-31 Merck Patent Gmbh Immunocytokines with modulated selectivity
JP4494977B2 (ja) 2002-12-17 2010-06-30 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｇｄ２に結合するマウス１４．１８抗体のヒト化抗体（ｈ１４．１８）およびそのｉｌ−２融合タンパク質
BRPI0418286A (pt) 2003-12-30 2007-05-02 Merck Patent Gmbh proteìnas de fusão de il-7
EP1706428B1 (en) 2004-01-22 2009-09-23 MERCK PATENT GmbH Anti-cancer antibodies with reduced complement fixation
US7670595B2 (en) 2004-06-28 2010-03-02 Merck Patent Gmbh Fc-interferon-beta fusion proteins
ATE555125T1 (de) 2005-12-30 2012-05-15 Merck Patent Gmbh Interleukin-12p40-varianten mit verbesserter stabilität
JP2009521912A (ja) 2005-12-30 2009-06-11 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング 低減された免疫原性を有する抗ｃｄ１９抗体
AU2010238858A1 (en) 2009-04-22 2011-12-08 Merck Patent Gmbh Antibody fusion proteins with modified FcRn binding sites
JP5879713B2 (ja) * 2010-12-09 2016-03-08 ソニー株式会社 画像処理装置、および画像処理方法、並びにプログラム
EP2537933A1 (en) 2011-06-24 2012-12-26 Institut National de la Santé et de la Recherche Médicale (INSERM) An IL-15 and IL-15Ralpha sushi domain based immunocytokines
CN109395064A (zh) 2013-04-19 2019-03-01 赛腾制药 降低的血管渗漏综合征的细胞因子衍生治疗
EP2915569A1 (en) 2014-03-03 2015-09-09 Cytune Pharma IL-15/IL-15Ralpha based conjugates purification method

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1564666A (en) * 1978-05-31 1980-04-10 Ng Mun Hon Heterocomplexes of interferon with immunoglobulin and pharmaceutical compositions thereof

Also Published As

Publication number Publication date
AU627694B2 (en) 1992-09-03
NO883896D0 (no) 1988-09-01
NZ226005A (en) 1990-10-26
PH26813A (en) 1992-11-05
ATE88900T1 (de) 1993-05-15
DK486588D0 (da) 1988-09-01
FI884013A (fi) 1989-03-03
NO883896L (no) 1989-03-03
KR890005137A (ko) 1989-05-13
EP0305967A2 (de) 1989-03-08
DE3880766D1 (de) 1993-06-09
ZA886471B (en) 1989-04-26
JPS6490200A (en) 1989-04-06
AU2172588A (en) 1989-03-23
EP0305967B1 (de) 1993-05-05
EP0305967A3 (en) 1990-01-31
IL87621A0 (en) 1989-01-31
PT88385B (pt) 1992-10-30
DK486588A (da) 1989-03-03
FI884013A0 (fi) 1988-08-31
PT88385A (pt) 1989-07-31

Similar Documents

Publication Publication Date Title
ES2054753T3 (es) Conjugados de citoquinas con inmunoglobulinas.
DE59101397D1 (de) O-glycosyliertes ifn-alpha.
ATE72991T1 (de) Nasale verabreichung von arzneimitteln.
ATE358176T1 (de) Menschliche dnase
AU586860B2 (en) Therapeutical application of phosphonylmethoxyalkyl adenines
NO940219L (no) Rekombinante antistoffer for human terapi
GEP19981482B (en) Use of 1,3 - Oxatiolan Nucleozides Analoges for Treatment of Hepatitis B
NO931413L (no) Fremgangsmaater og preparater for behandling av celleproliferasjonssykdommer
DE68912155T2 (de) Antivirales Kombinationspräparat.
NO891006D0 (no) Terapeutisk aktivt polypeptid og fremgangsmaate for dets fremstilling.
ATE67783T1 (de) Homogene rekombinante immun-interferon-fragmente und diese enthaltende pharmazeutische zusammensetzungen.
ES2115582T3 (es) Preparacion y aplicaciones de interferon-gamma.
ES2037807T3 (es) Medicamentos que contienen en combinacion interferon y 1-desoxi-piperidinosas, procedimiento para su fabricacion y su aplicacion.
ES2061496T3 (es) Tratamiento intralesional del carcinoma de celulas basales con alfa-interferon humano recombinante.
ES2039276T3 (es) Uso de una combinacion de interferon gamma e interferon alfa para la preparacion de un medicamento para el tratamiento de ciertas leucemias.
ATE92333T1 (de) Arzneimittel zur intralesionsbehandlung von schuppenartigem zellkarzinomen mit rekombinantem human-alpha-interferon.
DK0427633T3 (da) Anvendelse af et polypeptid med gammainterferonaktivitet til fremstilling af farmaceutiske præparater beregnet til behandling af primitiv pleuracancer
IT9086214A1 (it) Cura o guarigione del cancro o maurosalute

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 305967

Country of ref document: ES